Table 1 Patient characteristics for Swedish PMBL patients diagnosed 2007–2018 overall and stratified by immunochemotherapy regimen and radiotherapy.
Whole cohort N (%) | Immunochemotherapy regimen | Radiotherapy | |||||
|---|---|---|---|---|---|---|---|
R-CHOEP-14 | R-CHOP-14/21 | R-Hyper-CVAD | DA-EPOCH-R | Yes | No | ||
N | 172 | 90 | 37 | 16 | 11 | 26 | 129 |
Median age (range) | 37.5 (18–85) | 35 (18–74) | 49 (18–83) | 38 (21–51) | 41 (23–57) | 38.5 (20–70) | 36 (18–83) |
Sex | |||||||
Men | 74 (43) | 38 (42) | 18 (49) | 5 (31) | 5 (45) | 15 (58) | 51 (40) |
Women | 98 (57) | 52 (58) | 19 (51) | 11 (69) | 6 (55) | 11 (42) | 78 (60) |
WHO Performance status | |||||||
0–1 | 152 (88) | 81 (90) | 30 (81) | 15 (94) | 10 (91) | 23 (88) | 114 (88) |
Ann Arbor Stagea | |||||||
I–II | 116 (67) | 64 (71) | 26 (70) | 8 (50) | 8 (73) | 22 (85) | 85 (66) |
S-LDH | |||||||
Elevated | 154 (90) | 82 (91) | 30 (81) | 15 (94) | 11 (100) | 25 (96) | 113 (88) |
Extranodal sites | |||||||
No | 128 (74) | 69 (77) | 30 (81) | 12 (75) | 9 (82) | 20 (77) | 101 (78) |
aaIPI | |||||||
0–1 | 111 (64) | 61 (68) | 24 (65) | 9 (56) | 7 (64) | 20 (77) | 82 (64) |
2–3 | 61 (36) | 29 (32) | 13 (35) | 7 (44) | 4 (36) | 6 (23) | 47 (36) |
B-symptomsb | |||||||
Yes | 78 (45) | 42 (47) | 17 (46) | 7 (44) | 5 (45) | 16 (62) | 56 (43) |
Bulky diseasec | |||||||
Yes | 119 (69) | 68 (76) | 23 (62) | 15 (94) | 5 (45) | 20 (77) | 91 (70) |
Radiotherapy | |||||||
No | 129 (83) | 74 (82) | 32 (86) | 14 (88) | 8 (72) | 0 (0) | 129 (100) |
Yes | 26 (17) | 16 (18) | 5 (14) | 2(12) | 3 (27) | 26 (100) | 0 (0) |
